Regulatory approval is the gate most international beauty brands underestimate when entering Brazil. Here's how ANVISA works, what actually delays launches, and how to build it into your go-to-market plan.

Most market-entry conversations about Brazil start with distribution, pricing, or creator strategy. They should start with ANVISA, the national health surveillance agency that regulates every cosmetic, personal care, and perfumery product sold in the country. Get this step wrong and the best go-to-market plan in the world sits on a shelf waiting for paperwork.
Brazil has one of the most structured — and most misunderstood — cosmetic regulatory systems in LATAM. Unlike the EU or US, where many cosmetics can go to market with minimal pre-clearance, Brazil requires products to be formally registered or notified before they can legally be sold, advertised, or even sampled commercially. International teams used to lighter-touch regimes consistently underestimate the lead time this adds to launch planning.
ANVISA classifies cosmetic products into two risk grades:
The grade a product falls into changes almost everything downstream: the documentation required, the review pathway, and how long the process realistically takes.
While specifics vary by category, the general sequence looks like this:
In our work supporting international brands entering Brazil, the same mistakes show up again and again:
The brands that launch smoothly in Brazil treat ANVISA timing as a planning input from day one, not a compliance afterthought bolted onto a marketing calendar. That means sequencing: identifying which SKUs to prioritize for registration based on commercial potential, and building sampling, creator, and launch campaigns around realistic approval windows rather than wishful ones.
This is where market intelligence earns its keep. Rather than registering an entire catalog and hoping demand matches it, brands can use first-party purchase and search behavior from the Brazilian market — the kind of data BIA aggregates — to prioritize which categories and formulations are worth the regulatory investment first. A trend read from TendencyAI can tell you which format or claim is gaining traction locally before you commit a dossier to it.
B4A doesn't file your ANVISA paperwork — that work belongs with specialized regulatory counsel. What B4A does is help brands make smarter decisions about what to register and in what order, using Brazilian consumer and purchase data to de-risk the commercial side of market entry while the regulatory track runs in parallel. Combined with sampling and creator infrastructure ready to activate the moment a SKU clears, that alignment is often the difference between a six-month delay and a coordinated launch.
B4A Serviços de Tecnologia e Comércio S.A.
Avenida Jornalista Roberto Marinho, nº 85, 11º Andar (Conjunto 112), Cidade Monções - CEP 04576-010 - Cidade de São Paulo, Estado de São Paulo